{"id":"fenquizone","rwe":[{"pmid":"2179289","year":"1990","title":"Hemodynamic and humoral effects of chronic antihypertensive treatment with fenquizone: importance of aldosterone response.","finding":"","journal":"Journal of clinical pharmacology","studyType":"Clinical Study"},{"pmid":"3311532","year":"1987","title":"Clinical pharmacokinetics of some newer diuretics.","finding":"","journal":"Clinical pharmacokinetics","studyType":"Clinical Study"},{"pmid":"3691123","year":"1987","title":"The effect of fenquizone on the urinary inhibitors of calcium oxalate urolithiasis.","finding":"","journal":"Contributions to nephrology","studyType":"Clinical Study"},{"pmid":"3902676","year":"1985","title":"Double-blind crossover study of fenquizone compared to chlorthalidone in essential hypertension.","finding":"","journal":"International journal of clinical pharmacology, therapy, and toxicology","studyType":"Clinical Study"},{"pmid":"4026929","year":"1985","title":"Single-dose pharmacokinetics of fenquizone in healthy volunteers.","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"}],"tags":[{"label":"fenquizone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C03BA13","category":"atc"},{"label":"Active","category":"status"},{"label":"Diuretics","category":"pharmacology"},{"label":"Natriuretic Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"m.g. 13054","offLabel":[],"synonyms":["M.G. 13054","MG 13054","fenquizone","idrolone","fenquizone potassium"],"timeline":[],"approvals":[],"brandName":"M.G. 13054","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"fenquizone","explanation":"Imagine your body's cells are like a factory, and enzymes are the workers that help make things happen. Fenquizone is like a tool that tries to stop one of these workers from doing their job, which can affect how the factory runs. However, the exact way it works is still not well understood.","oneSentence":"Fenquizone is thought to work by inhibiting a specific enzyme or pathway, although the exact mechanism is unclear.","technicalDetail":"Fenquizone is a small molecule that likely acts as a competitive inhibitor of a specific enzyme or receptor, although the precise molecular target and binding mechanism remain unknown."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1162","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FENQUIZONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:30:06.419177","biosimilars":[],"competitors":[{"drugName":"quinethazone","drugSlug":"quinethazone","fdaApproval":"1963-04-10","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"chlortalidone","drugSlug":"chlortalidone","fdaApproval":"1960-04-07","relationship":"same-class"},{"drugName":"metolazone","drugSlug":"metolazone","fdaApproval":"1973-11-27","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"indapamide","drugSlug":"indapamide","fdaApproval":"1983-07-06","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"fenquizone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"quinethazone","brandName":"quinethazone","genericName":"quinethazone","approvalYear":"1963","relationship":"same-class"},{"drugId":"chlortalidone","brandName":"chlortalidone","genericName":"chlortalidone","approvalYear":"1960","relationship":"same-class"},{"drugId":"metolazone","brandName":"metolazone","genericName":"metolazone","approvalYear":"1973","relationship":"same-class"},{"drugId":"indapamide","brandName":"indapamide","genericName":"indapamide","approvalYear":"1983","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"LJ1U13R8IK","CHEBI":"CHEBI:135435","INN_ID":"3444","UMLSCUI":"C0060196","ChEMBL_ID":"CHEMBL2106186","KEGG_DRUG":"D04161","DRUGBANK_ID":"DB13708","PUBCHEM_CID":"68548","SECONDARY_CAS_RN":"52246-40-9","MESH_SUPPLEMENTAL_RECORD_UI":"C007712"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":14,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"C03BA13","allCodes":["C03BA13"]},"biosimilarFilings":[],"recentPublications":[{"date":"1990 Mar","pmid":"2179289","title":"Hemodynamic and humoral effects of chronic antihypertensive treatment with fenquizone: importance of aldosterone response.","journal":"Journal of clinical pharmacology"},{"date":"1987 Oct","pmid":"3311532","title":"Clinical pharmacokinetics of some newer diuretics.","journal":"Clinical pharmacokinetics"},{"date":"1987","pmid":"3691123","title":"The effect of fenquizone on the urinary inhibitors of calcium oxalate urolithiasis.","journal":"Contributions to nephrology"},{"date":"1985 Sep","pmid":"3902676","title":"Double-blind crossover study of fenquizone compared to chlorthalidone in essential hypertension.","journal":"International journal of clinical pharmacology, therapy, and toxicology"},{"date":"1985","pmid":"4026929","title":"Single-dose pharmacokinetics of fenquizone in healthy volunteers.","journal":"Arzneimittel-Forschung"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fenquizone, also known as M.G. 13054, is a small molecule drug in the fenquizone class. Its original development is attributed to an unknown entity, and its current ownership is also unclear. The target of fenquizone is unknown, and it has not been approved by the FDA for any indications. The commercial status of fenquizone, including whether it is patented or generic, is also unknown. As a result, there is limited information available on its key safety considerations, half-life, bioavailability, and generic manufacturers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}